Durata Therapeutics To Host Reimbursement Seminar On April 23, 2013

CHICAGO, April 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it will host a reimbursement seminar for the investment community on Tuesday, April 23, 2013 at the NASDAQ MarketSite in New York City. The 90-minute seminar will begin at 10:00 a.m. Eastern Time and will be simultaneously webcast.

The seminar will be conducted by Avalere Health, LLC, a leading advisory company focused on healthcare business strategy and public policy, with the goal of providing an overview of the hospital and outpatient reimbursement landscape and market access in today's evolving healthcare environment.

Attendance at this event is by invitation only and space is limited. Professional investors and analysts wishing to attend should contact mricardo@duratatherapeutics.com, by Friday, April 12 th to register.

A live webcast of the presentation can be accessed from the Investor Relations section of the Company's website at www.duratatherapeutics.com . A replay of the presentation will also be available on the Durata website.

About Durata Therapeutics

Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, under investigation for the treatment of patients with ABSSSI caused by susceptible gram-positive bacteria.

Forward-looking statements

Statements contained in this press release contain forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
CONTACT: Investor Relations and Public Affairs Contact         Allison Wey         Durata Therapeutics, Inc.         Vice President, Investor Relations and Public Affairs         (312) 219-7017         awey@duratatherapeutics.com                  Media Relations Contact         Jed Weiner         White Oak Communications, Inc.         (847) 392-4186         jed.weiner@comcast.net

Durata Therapeutics, Inc. Logo

If you liked this article you might like

Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today

5 Stocks Moving on Unusual Volume

Emerging 'Superbugs' -- and Why Investors Should Care

2014 FDA Drug Approval Decision Calendar

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan